Home » Stocks » Sarepta Therapeutics

Sarepta Therapeutics, Inc. (SRPT)

Stock Price: $158.00 USD -0.03 (-0.02%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $158.50 +0.50 (0.32%) Aug 12, 4:09 PM

Stock Price Chart

Key Info

Market Cap 12.40B
Revenue (ttm) 450.19M
Net Income (ttm) -530.34M
Shares Out 78.51M
EPS (ttm) -7.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $158.00
Previous Close $158.03
Change ($) -0.03
Change (%) -0.02%
Day's Open 157.78
Day's Range 156.89 - 160.00
Day's Volume 608,928
52-Week Range 72.05 - 175.00

More Stats

Market Cap 12.40B
Enterprise Value 11.11B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 78.51M
Float 74.70M
EPS (basic) -7.03
EPS (diluted) -7.00
FCF / Share 3.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.89%
Payout Ratio n/a
Shares Short 10.66M
Short Ratio 15.96
Short % of Float 15.18%
Beta 1.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 53.01
PS Ratio 27.55
PB Ratio 11.90
Revenue 450.19M
Operating Income -610.19M
Net Income -530.34M
Free Cash Flow 233.99M
Net Cash 1.29B
Net Cash / Share 16.49
Gross Margin -52.52%
Operating Margin -135.54%
Profit Margin -117.80%
FCF Margin 51.97%
ROA -16.19%
ROE -49.52%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (22)

Buy 19
Overweight 2
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$196.40*
(24.30% upside)
Low
161
Current: $158.00
High
260
Target: 196.40
*Average 12-month price target from 20 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3813011555.421.259.7614.2237.3346.9929.42
Revenue Growth26.51%94.74%2751.58%332.64%-87.16%-31.38%-61.91%-20.56%59.72%-
Gross Profit3242671475.321.259.7614.2237.3346.9929.42
Operating Income-706-344-172-267-220-134-90.28-29.70-35.93-20.93
Net Income-715-362-50.69-267-220-136-112-121-2.32-32.18
Shares Outstanding73.6266.2558.8248.7042.2940.0333.8523.6021.6018.54
Earnings Per Share-9.71-5.46-0.86-5.49-5.20-3.39-3.31-5.14-0.11-1.74
Operating Cash Flow-456-389-232-246-149-129-64.70-29.69-23.68-15.21
Capital Expenditures-59.63-61.16-12.00-5.34-3.40-25.44-2.37-0.11-1.18-0.83
Free Cash Flow-516-450-244-251-153-154-67.07-29.80-24.86-16.04
Cash & Equivalents1,1251,1741,07932920421126518839.9033.59
Total Debt73042143116.1523.406.331.671.761.841.92
Net Cash / Debt39575364831218120526318638.0631.67
Assets1,8231,6421,30842427429529220554.3745.98
Liabilities1,00561051987.4183.4447.3844.3881.3123.3548.79
Book Value8181,03278933719024824712431.02-2.82
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sarepta Therapeutics, Inc.
Country United States
Employees 743
CEO Douglas S. Ingram

Stock Information

Ticker Symbol SRPT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SRPT
IPO Date June 3, 1997

Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.